HC Wainwright & Co. analyst Vernon Bernardino maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy, adjusts target to $19 from $2 (1-10 Reverse Stock Split).
HC Wainwright & Co. Maintains Buy on NRX Pharmaceuticals, Adjusts Price Target To $19 (1-10 Reverse Stock Split)
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.